Core tobacco remains resilient, but Shanks execution and tobacco oversupply constrain fiscal 2027 earnings visibility.
| Quarter | Q4 FY26 |
|---|---|
| Length | 33 minutes |
| EPS | $-0.46 |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q3 FY26 · Q1 FY26
All UVV earnings · Back to UVV overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.